Gamma glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 4, 2009, Pages 429-430

  Bani Sadr, Firouzé ^a   Lapidus, Nathanael ^a   Rosenthal, Eric ^b   Gerard, Laurence ^c   Foltzer, Adeline ^d   Perronne, Christian ^e   Cacoub, Patrice ^f   Pol, Stanislas ^a   Carrat, Fabrice ^a  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f Sorbonne Université   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; RIBAVIRIN;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; PRIORITY JOURNAL; VIRUS LOAD; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; ENZYMOLOGY; RANDOMIZED CONTROLLED TRIAL;

DRUG THERAPY, COMBINATION; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN;

EID: 64249130614     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819a2429     Document Type: Letter

References (10)

1. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721-725.
2. Carrât F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
3. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005;40:47-52.
4. Bani-Sadr F, Carrât F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIVand hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis. 2005;41:1806-1809.
5. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis. 2008;46:768-774.
6. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002;16:2165-2173.
7. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177-182.
8. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Labcet. 2001;357:280-281.
9. Guyader D, Poinsignon Y, Cano Y, et al. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol. 2002;37:289-291.
10. Bani-Sadr F, Miailhes P, Rosenthal E, et al. Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C viruscoinfected patients. AIDS. 2008;22:1234-1236.